Bayesian evaluation of group sequential clinical trial designs
- 25 October 2006
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 26 (7) , 1431-1449
Abstract
Clinical trial designs often incorporate a sequential stopping rule to serve as a guide in the early termination of a study. When choosing a particular stopping rule, it is most common to examine frequentist operating characteristics such as type I error, statistical power, and precision of confidence intervals (Statist. Med. 2005, in revision). Increasingly, however, clinical trials are designed and analysed in the Bayesian paradigm. In this paper, we describe how the Bayesian operating characteristics of a particular stopping rule might be evaluated and communicated to the scientific community. In particular, we consider a choice of probability models and a family of prior distributions that allows concise presentation of Bayesian properties for a specified sampling plan. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
All Related Versions
This publication has 15 references indexed in Scilit:
- Bayesian Statistics and the Efficiency and Ethics of Clinical TrialsStatistical Science, 2004
- Likelihood methods for measuring statistical evidenceStatistics in Medicine, 2002
- Bayes FactorsJournal of the American Statistical Association, 1995
- Bayesian Approaches to Randomized TrialsJournal of the Royal Statistical Society Series A: Statistics in Society, 1994
- A case for bayesianism in clinical trialsStatistics in Medicine, 1993
- Proper likelihoods for Bayesian analysisBiometrika, 1992
- Interim Analysis in Clinical Trials: The Role of the Likelihood PrincipleThe American Statistician, 1987
- Bootstrap methods using prior informationBiometrika, 1986
- Monitoring clinical trials: Conditional or predictive power?Controlled Clinical Trials, 1986
- On the Foundations of Statistical InferenceJournal of the American Statistical Association, 1962